Literature DB >> 15759101

Tyrosinaemia type I--de novo mutation in liver tissue suppressing an inborn splicing defect.

Y T Bliksrud1, E Brodtkorb, P A Andresen, I E T van den Berg, E A Kvittingen.   

Abstract

Many patients with tyrosinaemia type 1 have a mosaic pattern of fumarylacetoacetase (FAH) immunopositive or immunonegative nodules in liver tissue. This phenomenon has been explained by a spontaneous reversion of the mutation in one allele to a normal genotype, but only a few nodules have been examined. We now report on a Norwegian patient, compound heterozygous for the mutations IVS12g(+5)-->a and G(1009-->)A, with liver mosaicism, but with an immunopositive nodule in which both primary mutations were intact. In the immunopositive hepatocytes of this nodule, genetic analyses showed a new mutation, C(1061-->)A, 6 bp upstream of the primary mutation IVS12g(+5)-->a in the FAH gene. The splicing defect caused by the primary mutation is most likely suppressed by the new mutation due to improvement of the splicing site. In the same liver we demonstrate another nodule of regenerating immunopositive tissue due to reversion of one of the primary mutations to a normal genotype. Together with the original cells this makes a triple mosaicism of hepatocytes with one, two or three point mutations in the FAH gene.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15759101     DOI: 10.1007/s00109-005-0648-2

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  9 in total

1.  Partial restoration of degraded DNA from archival paraffin-embedded tissues.

Authors:  E N Imyanitov; M Y Grigoriev; V M Gorodinskaya; E S Kuligina; K M Pozharisski; A V Togo; K P Hanson
Journal:  Biotechniques       Date:  2001-11       Impact factor: 1.993

2.  Adenosine deaminase deficiency with mosaicism for a "second-site suppressor" of a splicing mutation: decline in revertant T lymphocytes during enzyme replacement therapy.

Authors:  Francisco X Arredondo-Vega; Ines Santisteban; Eva Richard; Pawan Bali; Majed Koleilat; Michael Loubser; Abdulaziz Al-Ghonaium; Mariam Al-Helali; Michael S Hershfield
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

3.  Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect.

Authors:  E A Kvittingen; H Rootwelt; P Brandtzaeg; A Bergan; R Berger
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

4.  Analysis of canonical and non-canonical splice sites in mammalian genomes.

Authors:  M Burset; I A Seledtsov; V V Solovyev
Journal:  Nucleic Acids Res       Date:  2000-11-01       Impact factor: 16.971

5.  Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes.

Authors:  J Poudrier; F Lettre; C R Scriver; J Larochelle; R M Tanguay
Journal:  Mol Genet Metab       Date:  1998-06       Impact factor: 4.797

Review 6.  In vivo reversion to normal of inherited mutations in humans.

Authors:  R Hirschhorn
Journal:  J Med Genet       Date:  2003-10       Impact factor: 6.318

7.  Self-induced correction of the genetic defect in tyrosinemia type I.

Authors:  E A Kvittingen; H Rootwelt; R Berger; P Brandtzaeg
Journal:  J Clin Invest       Date:  1994-10       Impact factor: 14.808

8.  Tyrosinemia type 1--complex splicing defects and a missense mutation in the fumarylacetoacetase gene.

Authors:  H Rootwelt; T Kristensen; R Berger; K Høie; E A Kvittingen
Journal:  Hum Genet       Date:  1994-09       Impact factor: 4.132

9.  A missense mutation (Q279R) in the fumarylacetoacetate hydrolase gene, responsible for hereditary tyrosinemia, acts as a splicing mutation.

Authors:  N Dreumont; J A Poudrier; A Bergeron; H L Levy; F Baklouti; R M Tanguay
Journal:  BMC Genet       Date:  2001-06-29       Impact factor: 2.797

  9 in total
  10 in total

1.  Point mutation instability (PIN) mutator phenotype as model for true back mutations seen in hereditary tyrosinemia type 1 - a hypothesis.

Authors:  Etresia van Dyk; Pieter J Pretorius
Journal:  J Inherit Metab Dis       Date:  2011-10-15       Impact factor: 4.982

Review 2.  Cutaneous mosaicism: right before our eyes.

Authors:  Jorge Frank; Rudolf Happle
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

3.  Tissue-specific FAH deficiency alters sleep-wake patterns and results in chronic tyrosinemia in mice.

Authors:  Shuzhang Yang; Sandra M Siepka; Kimberly H Cox; Vivek Kumar; Marleen de Groot; Yogarany Chelliah; Jun Chen; Benjamin Tu; Joseph S Takahashi
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-14       Impact factor: 11.205

4.  Multiple correcting COL17A1 mutations in patients with revertant mosaicism of epidermolysis bullosa.

Authors:  Anna M G Pasmooij; Hendri H Pas; Franciska C L Deviaene; Miranda Nijenhuis; Marcel F Jonkman
Journal:  Am J Hum Genet       Date:  2005-09-09       Impact factor: 11.025

5.  Geographical and Ethnic Distribution of Mutations of the Fumarylacetoacetate Hydrolase Gene in Hereditary Tyrosinemia Type 1.

Authors:  Francesca Angileri; Anne Bergeron; Geneviève Morrow; Francine Lettre; George Gray; Tim Hutchin; Sarah Ball; Robert M Tanguay
Journal:  JIMD Rep       Date:  2015-02-15

6.  Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3.

Authors:  Anna M G Pasmooij; Hendri H Pas; Maria C Bolling; Marcel F Jonkman
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

7.  Fumarylacetoacetate inhibits the initial step of the base excision repair pathway: implication for the pathogenesis of tyrosinemia type I.

Authors:  Yngve T Bliksrud; Amund Ellingsen; Magnar Bjørås
Journal:  J Inherit Metab Dis       Date:  2012-11-09       Impact factor: 4.982

8.  Multi-tissue computational modeling analyzes pathophysiology of type 2 diabetes in MKR mice.

Authors:  Amit Kumar; Thomas Harrelson; Nathan E Lewis; Emily J Gallagher; Derek LeRoith; Joseph Shiloach; Michael J Betenbaugh
Journal:  PLoS One       Date:  2014-07-16       Impact factor: 3.240

9.  The somatic FAH C.1061C>A change counteracts the frequent FAH c.1062+5G>A mutation and permits U1snRNA-based splicing correction.

Authors:  Daniela Scalet; Claudia Sacchetto; Francesco Bernardi; Mirko Pinotti; Stan F J van de Graaf; Dario Balestra
Journal:  J Hum Genet       Date:  2018-03-01       Impact factor: 3.172

Review 10.  A six-attribute classification of genetic mosaicism.

Authors:  Luis A Pérez-Jurado; Víctor L Ruiz Pérez; Antonio Torrelo; Nancy B Spinner; Rudolf Happle; Leslie G Biesecker; Pablo Lapunzina; Víctor Martínez-Glez; Jair Tenorio; Julián Nevado; Gema Gordo; Lara Rodríguez-Laguna; Marta Feito; Raúl de Lucas
Journal:  Genet Med       Date:  2020-07-14       Impact factor: 8.864

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.